此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer (APRIL)

2026年9月21日 更新者:Aman Sharma、All India Institute of Medical Sciences

The APRIL Trial: A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer

The aim of the study is to test the feasibility & loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.

研究概览

地位

尚未招聘

详细说明

The standard of care for unresectable stage III NSCLC lung cancer is combination chemoradiotherapy and best results are achieved when radiation is given along with concurrent chemotherapy. Concurrent chemoradiotherapy (CRT) is associated an overall survival rate at 5 years between 15%-32%.

Local relapse in stage III NSCLC can vary from 20% to 50%. Conventional radiation therapy results in high local failure rates that theoretically could act as a nidus for metastasis. For NSCLC, there is a proposed dose effect on local control and survival with doses of at least 70 Gy and tumors with volumes >100 cc require higher doses for better local control. However, in a prospective randomized controlled trial setting, CRT dose escalation with conventional radiotherapy was associated with inferior local control, PFS, OS and higher toxicity.

Stereotactic body radiotherapy (SBRT) delivers high dose conformal radiation through multiple radiation beams with steep dose gradients in 3-8 fractions and has shown limited toxicity despite delivering a high dose BED10>100 in early NSCLC. Local control in early-stage NSCLC with SBRT is around 85-90% . One landmark paper demonstrated significant survival benefits for stage I lung cancer with SBRT doses of biological equivalent (BED)10 in excess of 100 Gy. SBRT with BED10>100 Gy has convincingly achieved excellent treatment out comes in early-stage NSCLC. Similar local control may be achieved SBRT in stage III NSCLC provided safe dose of BED10>100 Gy is delivered. This holds true when tumor diameter is ≤ 6 cms.

SBRT has been combined with conventional CRT in stage III NSCLC with intent to decrease local failure. A recently conducted systematic review of SBRT in inoperable stage III NSCLC has published SBRT outcomes .In this systematic review, 6 studies considered SBRT administration in stage III NSCLC, 1 employed SBRT in monotherapy and 5 employed SBRT as dose escalation after conventional chemoradiotherapy. Median dose of conventional radiotherapy was 50.4 Gy in 28 fractions and median dose of SBRT boost was 22.25 Gy in 2 to 7 fractions. SBRT was used to treat primary tumor and involved lymph nodes in 3 out of 5 studies. The systematic review concluded that dose-escalation with 2 fraction SBRT (20-24 Gy) was feasible and was associated with local control rate of 78% at 1 year with 3.7% grade 5 and 14.2% grade 3toxicity.

There is data emerging on use of SBRT as monotherapy in stage III NSCLC. Ultra-central tumors in a study were treated with SBRT to primary and lymph nodes to a dose of 35 Gy in 5 fractions. Despite large tumors (median tumor diameter was 6.8 cm [range: 2.1-12.4 cms] and ultra-central location median local control was 17 months for stage III patients. Grade 3 or higher toxicity was observed in 9.8% of patients. Another phase II trials examined the feasibility of SBRT is locally advanced NSCLC. The prescribed doses were 30 Gy/5daily fractions at the reference isodose (60-70%) to the tumor, and 25 Gy/5 daily fractions to the clinically involved lymph nodes. Median follow-up was 87 months (range: 6-87), local PFS was 19.8 months (95% CI 9.7 - not reached), OS was 23 months. Late toxicity was represented by 24% dyspnea G3.

Hilar/mediastinal SBRT is a safe technique for isolated nodal disease . A retrospective study that treated 40 patients of NSCLC with SBRT for primary/oligorecurrent hilar/mediastinal lymph nodes. The median dose of SBRT was 48 Gy in 4 fractions. The aortico-pulmonary window was the target in 40%, hilum in 25%, lower paratracheal in 20%, subcarinal in 10%, and prevascular in 5%. Acute grade 3+ morbidity was seen in 3 patients (hemoptysis, pericardial/pleural effusion, heart failure) and late grade 3+ morbidity (hemoptysis) in 1 patient. A systematic review of SBRT on mediastinal & hilar lymph nodes that included 196 patients has been recently conducted. Non-small cell lung cancer (NSCLC) was the most common primary (65%) tumor subjected to mediastinal & hilar node SBRT. The reported dose and fractionation ranged from 21 Gy to 60 Gy in 3-11 fractions, with median BED ranged from 46-106 Gy. SBRT was associated with excellent local control (LC) rates of 69%-97% & 1 year OS of 69%-75%. Pooled grade 3-5 toxicity rate according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was 6% (n=11). Pooled SABR-related mortality (grade 5 toxicity) rate was 2% (n=4). Three SABR-related deaths from esophageal fistulae (2 to trachea, 1 to mediastinum) were reported, with all 3 having prior RT to the subcarinal nodes Given the safety & excellent efficacy of SBRT for small tumors (≤ 6cms) as well as hilar & mediastinal lymph nodes, the present phase study is designed evaluate SBRT in stage III NSCLC.

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Haryana
      • Jhajjar、Haryana、印度、124105

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Aged 18 or above and less than 75 years.
  2. Histologically proven non-small cell lung cancer.
  3. Stage T1-4, N1-3, M0 with maximum tumor size less than 6 cms and ≤ 3 stations of largest lymph node size less than 4 cms.
  4. ECOG status 0-1.
  5. Available to attend long term follow- up.
  6. Written informed consent for treatment.

Exclusion Criteria:

  1. Metastatic disease.
  2. Tumor size > 6cm.
  3. Involved Lymph node size greater than 4 cms & more than 3 station of lymph nodes involved.
  4. Patients with superior vena cava obstruction.
  5. Tumor invading/encasing the proximal bronchial tree/, esophagus, pericardium.
  6. Previous radiotherapy to thorax.
  7. Small cell histology.
  8. Age< 18 or > 75 years.
  9. Patients on anticoagulant therapy & ultra-central cavitary tumors.
  10. Poor performance status ECOG 2-3.
  11. Immunocompromised states.
  12. Viral Markers negative.
  13. Pregnant women

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:SBRT in stage III NSCLC

The study will evaluate efficacy & toxicity of SBRT in stage III NSCLC

SBRT to primary tumor and lymph nodes in stage III NSCLC when gross disease is < 6 cms

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Loco-regional control rate
大体时间:2 years

Loco regional control rate assessment till 2 years

2 years

次要结果测量

结果测量
措施说明
大体时间
Disease free survival
大体时间:2 years

Longitudinal assessment every 2 months for initial six months and every 3 months till next 2 years

2 years
Overall survival
大体时间:2 years

Longitudinal assessment every 2 months for initial six months and every 3 months till next 2 years

2 years
CTCAE V5 Toxicity
大体时间:2 years

CTCAE Grades

Grade refers to the severity of the adverse event. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline:

Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental ADL*.

Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**.

Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

Assessed at base line, post SBRT, post Chemotherapy, first follow up, at 6 months and then 6 monthly

2 years
EORTC QLQ C30 Quality of life
大体时间:2 years

The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.

Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. High score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

Assessed at base line, post SBRT, post Chemotherapy, first follow up, at 6 months and then 6 monthly

2 years
EORTC LC-13 Quality of life
大体时间:2 years

The lung cancer module incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis. It has scoring system from 1 to 4, higher score represents higher symptom burden.

Assessed at base line, post SBRT, post Chemotherapy, first follow up, at 6 months and then 6 monthly

2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月19日

初级完成 (估计的)

2029年12月18日

研究完成 (估计的)

2029年12月18日

研究注册日期

首次提交

2022年12月5日

首先提交符合 QC 标准的

2026年4月30日

首次发布 (实际的)

2026年5月4日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅